Effects of retinoic acid receptor-selective agonists on human nasal epithelial cell differentiation.
Retinoids play a critical role in the maintenance of the mucociliary phenotype of epithelial cells in the upper respiratory tract. To determine the role of retinoic acid receptors (RARs) in the regulation of epithelial differentiation, we tested the effect of the synthetic retinoids CD336, CD2019, and CD666, selective agonists for RARalpha, RARbeta, and RARgamma, respectively, during differentiation of human nasal epithelial (HNE) cells in vitro. Using glutamylated tubulin and transglutaminase I (Tg I) as markers of ciliated cell and squamous cell differentiation, respectively, we showed that retinoic acid (RA) stimulated mucociliary differentiation and, in parallel, inhibited squamous cell differentiation. The agonists of the three RARs independently induced ciliogenesis and inhibited squamous cell differentiation by downregulating Tg I expression in a dose- and time-dependent manner. Antagonists specific for the three RARs abolished the effects of the corresponding agonists, demonstrating an RAR-specific mediated effect. Moreover, treatment of retinoid-deficient cultures with RAR agonists induced conversion of the squamous-like phenotype into a ciliated phenotype. In conclusion, all three RARs are potentially involved in the differentiating effects of RA in respiratory epithelial cells.
Million
K
K
Laboratoire de Cytophysiologie et Toxicologie Cellulaire, Paris; and Galderma, Research and Development, Valbonne, France. million@paris7.jussieu.fr
Tournier
F
F
Houcine
O
O
Ancian
P
P
Reichert
U
U
Marano
F
F
D001565:Benzoates / Q000494:pharmacology*; D015415:Biomarkers; D002454:Cell Differentiation / Q000187:drug effects; D002467:Cell Nucleus / Q000378:metabolism; D002923:Cilia / Q000648:ultrastructure; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D008855:Microscopy, Electron, Scanning; D009281:Naphthalenes / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000166:cytology / Q000187:drug effects*; D009298:Nasal Polyps / Q000473:pathology; D018168:Receptors, Retinoic Acid / Q000819:agonists* / Q000502:physiology; D000072482:Retinoic Acid Receptor alpha; D012176:Retinoids / Q000494:pharmacology*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D011503:Transglutaminases / Q000032:analysis; D014404:Tubulin / Q000032:analysis; D000097768:Retinoic Acid Receptor gamma
D001565:Benzoates; D015415:Biomarkers; D009281:Naphthalenes; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D011503:Transglutaminases; D014404:Tubulin; D000097768:Retinoic Acid Receptor gamma; C101407:CD 2019; C445667:CD 666; C000607071:RARA protein, human; C082925:retinoic acid receptor beta; C068073:Am 580; C105804:transglutaminase 1